^
Association details:
| Biomarker: | TSPYL1 P62S |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer
Excerpt:
Data from a prospective clinical trial of 87 metastatic castration‐resistant prostate cancer patients treated with abiraterone acetate/prednisone showed that the variant SNP genotype (A) was significantly associated with worse response and progression‐free survival.
DOI:
https://doi.org/10.1002/cpt.907
Trial ID:
